Loading…
← CockpitCompetitor Analysis › 688277.SS Tinavi Medical Technologies Co., Ltd. Class AOpen in the cockpit ↗

Tinavi Medical Technologies Co., Ltd. Class A688277.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese pioneer of orthopedic and spine surgical robots that guide implant placement during surgery.

≈ A Chinese Mazor Robotics/Stryker Mako for orthopedic surgery roboticsMomentum weak 23
Mkt cap
$872M
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$21.0M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-16.0 pp
WACC 8.5%
Hurdle
n/a
no reverse DCF
Next earnings
161 days
28 Apr 2027
Close · CNYCN¥12.62
1D-4.2%
1W-20.8%
1M-14.4%
3M-24.7%
6M-36.5%
YTD-16.9%
1Y-29.4%
ATR %7.0%
52w lowhigh56.6% off high

What Tinavi Medical Technologies does

Chinese pioneer of orthopedic and spine surgical robots that guide implant placement during surgery.

Sells surgical robots to hospitals as large capital purchases, so sales depend on hospital equipment budgets and approvals in China. Surgeon training and procedure volumes decide whether installed robots keep being used and justify further purchases.

In one line: A Chinese Mazor Robotics/Stryker Mako for orthopedic surgery robotics.

Products and services

  • Spine surgery robots
  • Orthopedic trauma surgery robots
  • Joint replacement robots

Customers

  • Orthopedic/spine surgeons
  • Hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Orthopedic/spine surgical robotics

What could go right

  • Robotic-assisted surgery adoption in China

What could go wrong

  • High capex sales cycle
  • Hospital budget constraints

Moat: narrow (IP / patents, regulatory licence). First-mover Chinese approvals and patented navigation robotics create an early lead.

Headquarters: Beijing, China · Founded: 2005 · Employees: 334

Named competitors

Tinavi Medical Technologies at a glance

Size Tinavi Medical Technologies (688277.SS) is a China Health Care company (Medical Specialties) with a market value of $872M, the 2429th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.62 on 18 Nov 2026.

Performance Over six months the shares fell 36.5%, against -15.1% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue fell 2.3% over the last twelve months (peer median +10.4%); the operating margin is -58.7% (peer median 10.0%).

Valuation It trades at 21.7× enterprise value to sales against a peer median of 3.5× (most expensive of 21).

Capital Return on invested capital runs 16.0 points below its cost of capital (8.5% WACC).

Next results Next results expected around 28 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 85688277.SS 66
Six months, rebased to 100: Tinavi Medical Technologies against the median of its 20 peers (local-currency closes).

Tinavi Medical Technologies financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥268MCN¥279MCN¥179MCN¥209MCN¥156M
Revenue growth—+56%-15%+34%—
Gross profitCN¥188MCN¥156MCN¥99.3MCN¥121MCN¥85.1M
EBITDAn/a-CN¥131M-CN¥115M-CN¥167M-CN¥125M
Net income-CN¥164M-CN¥183M-CN¥121M-CN¥156M-CN¥111M
Free cash flow-CN¥203M-CN¥85.0M-CN¥135M-CN¥395M-CN¥144M
Capital expenditureCN¥29.6MCN¥29.7MCN¥36.7MCN¥221MCN¥59.6M
Total debtCN¥207MCN¥197MCN¥199MCN¥220MCN¥98.4M

Quarterly statements and history in the cockpit →

Tinavi Medical Technologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%688626688767002658688575688656301602301580BVS3600AORTKURNKIDS688068MCAPAMS096530290650688277.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Tinavi Medical Technologies is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×10×20×688626688767002658688575688656301602301580BVS3600603367AORTKURN1187688805688068096530290650688277.SSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tinavi Medical Technologies is the large dot.

Tinavi Medical Technologies competitors and peer comparison

Head to head with its named competitors (688277.SS vs MDT vs SYK vs 688198.SS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Tinavi Medical Technologies 688277.SS$872M-36%-2%-59%21.7×n/a
Medtronic MDT$129B+30%+10%20%4.0×9.1%
Stryker SYK$121B-1%+8%25%5.1×10.7%
Beijing Balance Medical Technology 688198.SS$1.31B-32%+10%28%13.4×20.7%

How Tinavi Medical Technologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tinavi Medical Technologies against its 20 peers (data as of 18 Nov 2026)
Measure688277.SSPeer medianRank in peer set
1-month return-14.4%-8.0%6th lowest of 21
6-month return-36.5%-15.1%4th lowest of 21
Distance from 52-week high-56.6%-41.9%6th lowest of 21
Revenue growth (TTM)-2.3%+10.4%4th lowest of 21
Operating margin-58.7%10.0%2nd lowest of 21
EV / Sales21.7×3.5×most expensive of 21
ROIC minus cost of capital-16.0 pp+2.0 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%21.7×n/an/a
Xiangyu Medical 688626.SSChina$877M-38%0%4%7.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%10.4×n/an/a
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%3.3×16.8%+2.9%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%3.1×2.0%+12.7%
HOB Biotech 688656.SSChina$858M-33%+6%7%13.7×37.6%+12.4%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%12.0×11.1%+4.6%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%4.0×19.3%+23.3%
Bioventus BVSUnited States$895M-3%+4%10%2.0×7.5%+12.1%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%1.6×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%0.7×-14.6%-1.3%
Artivion AORTUnited States$905M-18%+14%5%2.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%5.5×n/an/a
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%1.0×-6.4%+6.6%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%3.4×n/an/a
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%6.8×35.6%+17.1%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%9.6×n/an/a
MedCap MCAP.STSweden$811M-4%+17%15%3.6×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%3.0×20.0%+21.4%
Seegene 096530.KSSouth Korea$808M-26%+13%13%1.2×-6.7%-15.9%
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%9.7×32.6%+21.0%

Questions

Who are Tinavi Medical Technologies's main competitors?
Named competitors: Medtronic (Mazor) (MDT), Stryker (Mako) (SYK), Beijing Balance Medical (688198.SS). The cockpit's measured peer set (industry) also includes Xiangyu Medical (688626.SS), Hangzhou Biotest Biotech (688767.SS), Beijing SDL Technology (002658.SZ), Shenzhen YHLO Biotech (688575.SS), HOB Biotech (688656.SS), Shantou Institute of Ultrasonic Instruments (301602.SZ).
Is Tinavi Medical Technologies expensive compared with its peers?
On ev / sales it trades at 21.7× against a peer median of 3.5×, most expensive of 21 in its peer set.
How has Tinavi Medical Technologies stock performed?
Over six months to 18 Nov 2026 the shares returned -36.5% against -15.1% for the median peer; over one year -29.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.